STATUS: Recruiting

SPONSOR: Seagen Inc.
LEAD GROUP: BGOG
ENGOT Model: C
TITLE: A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
ClinicalTrials.gov ID:  NCT04697628
MaNGO sites (click to see the list)

STATUS: Recruiting

SPONSOR: AstraZeneca
LEAD GROUP: GEICO
ENGOT Model: C
TITLE: A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
ClinicalTrials.gov ID:  NCT06079671
MaNGO sites (click to see the list)

STATUS: Recruiting

SPONSOR: Merck Sharp & Dohme LLC
LEAD GROUP: NSGO
ENGOT Model: C
TITLE: A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer
ClinicalTrials.gov ID:  NCT06459180
MaNGO sites (click to see the list)